Clinicopathological Significance of SPC18 in Colorectal Cancer: SPC18 Participates in Tumor Progression

Overview

Journal Cancer Sci

Specialty Oncology

Date 2016 Nov 19

PMID 27859949

Citations 10

Authors

Takuya Hattori

Kazuhiro Sentani

Oue Naohide

Naoya Sakamoto

Wataru Yasui

Affiliations

Soon will be listed here.

Abstract

Colorectal cancer (CRC) is one of the leading causes of cancer-related death worldwide. In order to identify novel prognostic markers or therapeutic targets for CRC, we searched for candidate genes in our comprehensive gene expression libraries, and focused on SEC11A, which encodes the SPC18 protein. SPC18 plays a key role in the endoplasmic reticulum-Golgi secretory pathway and presumably regulates the secretion of various secretory proteins. An immunohistochemical analysis of SPC18 in 137 CRC tissue samples demonstrated that 79 (58%) CRC cases were positive for SPC18. SPC18-positive CRC cases were more advanced in terms of N classification (P = 0.0315) and tumor stage (P = 0.0240) than SPC18-negative CRC cases. Furthermore, the expression of SPC18 was an independent prognostic classifier for CRC patients. The cell growth and invasiveness of SPC18 siRNA-transfected CRC cell lines was less than that of the negative control siRNA-transfected cell lines. The levels of phosphorylated epidermal growth factor receptor, Erk and Akt were lower in SPC18 siRNA-transfected CRC cells than in control cells. The expression of SPC18 was colocalized with β-catenin nuclear localization and MMP7 at the invasive front. An immunohistochemical analysis of human colorectal polyp specimens revealed a sequential increase in the expression of SPC18 through the conventional adenoma-carcinoma pathway, while SPC18 was not expressed or was expressed to a lesser extent in serrated pathway-related tumors. These results suggest that SPC18 is involved in tumor progression, and is an independent prognostic classifier in patients with CRC.

Citing Articles

SEC11A contributes to tumour progression of head and neck squamous cell carcinoma.

Shen H, Yi F, Ding Z, Liu W, Liu P, Wang Z Heliyon. 2023; 9(4):e14958.

PMID: 37025806 PMC: 10070141. DOI: 10.1016/j.heliyon.2023.e14958.

Signal peptidase complex catalytic subunit SEC11A upregulation is a biomarker of poor prognosis in patients with head and neck squamous cell carcinoma.

Hu C, Fan J, He G, Dong C, Zhou S, Zheng Y PLoS One. 2022; 17(6):e0269166.

PMID: 35653344 PMC: 9162331. DOI: 10.1371/journal.pone.0269166.

Clinicopathological significance of claspin overexpression and its efficacy as a novel biomarker for the diagnosis of urothelial carcinoma.

Kobayashi G, Hayashi T, Sentani K, Babasaki T, Sekino Y, Inoue S Virchows Arch. 2021; 480(3):621-633.

PMID: 34842980 DOI: 10.1007/s00428-021-03239-7.

Overexpression of claspin promotes docetaxel resistance and is associated with prostate-specific antigen recurrence in prostate cancer.

Babasaki T, Sentani K, Sekino Y, Kobayashi G, Pham Q, Katsuya N Cancer Med. 2021; 10(16):5574-5588.

PMID: 34240817 PMC: 8366092. DOI: 10.1002/cam4.4113.

KHDRBS3 promotes multi-drug resistance and anchorage-independent growth in colorectal cancer.

Ukai S, Sakamoto N, Taniyama D, Harada K, Honma R, Maruyama R Cancer Sci. 2021; 112(3):1196-1208.

PMID: 33423358 PMC: 7935809. DOI: 10.1111/cas.14805.

References

Sharma M, Sah P, Sharma S, Radhakrishnan R . Molecular changes in invasive front of oral cancer. J Oral Maxillofac Pathol. 2013; 17(2):240-7. PMC: 3830234. DOI: 10.4103/0973-029X.119740. View

Popat S, Hubner R, Houlston R . Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005; 23(3):609-18. DOI: 10.1200/JCO.2005.01.086. View

Yasui W, Sano T, Nishimura K, Kitadai Y, Ji Z, Yokozaki H . Expression of P-cadherin in gastric carcinomas and its reduction in tumor progression. Int J Cancer. 1993; 54(1):49-52. DOI: 10.1002/ijc.2910540109. View

Takeuchi K, Ito F . EGF receptor in relation to tumor development: molecular basis of responsiveness of cancer cells to EGFR-targeting tyrosine kinase inhibitors. FEBS J. 2009; 277(2):316-26. DOI: 10.1111/j.1742-4658.2009.07450.x. View

Vignjevic D, Schoumacher M, Gavert N, Janssen K, Jih G, Lae M . Fascin, a novel target of beta-catenin-TCF signaling, is expressed at the invasive front of human colon cancer. Cancer Res. 2007; 67(14):6844-53. DOI: 10.1158/0008-5472.CAN-07-0929. View

Seko N, Oue N, Noguchi T, Sentani K, Sakamoto N, Hinoi T . Olfactomedin 4 (GW112, hGC-1) is an independent prognostic marker for survival in patients with colorectal cancer. Exp Ther Med. 2012; 1(1):73-78. PMC: 3490347. DOI: 10.3892/etm_00000013. View

Jass J, Iino H, Ruszkiewicz A, Painter D, Solomon M, Koorey D . Neoplastic progression occurs through mutator pathways in hyperplastic polyposis of the colorectum. Gut. 2000; 47(1):43-9. PMC: 1727952. DOI: 10.1136/gut.47.1.43. View

Murakami T, Mitomi H, Saito T, Takahashi M, Sakamoto N, Fukui N . Distinct WNT/β-catenin signaling activation in the serrated neoplasia pathway and the adenoma-carcinoma sequence of the colorectum. Mod Pathol. 2014; 28(1):146-58. DOI: 10.1038/modpathol.2014.41. View

Oue N, Kuniyasu H, Noguchi T, Sentani K, Ito M, Tanaka S . Serum concentration of Reg IV in patients with colorectal cancer: overexpression and high serum levels of Reg IV are associated with liver metastasis. Oncology. 2008; 72(5-6):371-80. DOI: 10.1159/000113147. View

10.

Sentani K, Sakamoto N, Shimamoto F, Anami K, Oue N, Yasui W . Expression of olfactomedin 4 and claudin-18 in serrated neoplasia of the colorectum: a characteristic pattern is associated with sessile serrated lesion. Histopathology. 2013; 62(7):1018-27. DOI: 10.1111/his.12099. View

11.

Chua Y, Zalcberg J . Progress and challenges in the adjuvant treatment of stage II and III colon cancers. Expert Rev Anticancer Ther. 2008; 8(4):595-604. DOI: 10.1586/14737140.8.4.595. View

12.

Kobayashi T, Hino S, Oue N, Asahara T, Zollo M, Yasui W . Glycogen synthase kinase 3 and h-prune regulate cell migration by modulating focal adhesions. Mol Cell Biol. 2006; 26(3):898-911. PMC: 1347031. DOI: 10.1128/MCB.26.3.898-911.2006. View

13.

Kang M, Ryu B, Lee M, Han J, Lee J, Ha T . NF-kappaB activates transcription of the RNA-binding factor HuR, via PI3K-AKT signaling, to promote gastric tumorigenesis. Gastroenterology. 2008; 135(6):2030-42, 2042.e1-3. DOI: 10.1053/j.gastro.2008.08.009. View

14.

Nickel W, Rabouille C . Mechanisms of regulated unconventional protein secretion. Nat Rev Mol Cell Biol. 2009; 10(2):148-55. DOI: 10.1038/nrm2617. View

15.

Hattori T, Sentani K, Naohide O, Sakamoto N, Yasui W . Clinicopathological significance of SPC18 in colorectal cancer: SPC18 participates in tumor progression. Cancer Sci. 2016; 108(1):143-150. PMC: 5276824. DOI: 10.1111/cas.13121. View

16.

Younes M, Fernandez L, Lechago J . Transforming growth factor alpha (TGF-alpha) expression in biopsies of colorectal carcinoma is a significant prognostic indicator. Anticancer Res. 1996; 16(4A):1999-2003. View

17.

Sakamoto N, Oue N, Sentani K, Anami K, Uraoka N, Naito Y . Liver-intestine cadherin induction by epidermal growth factor receptor is associated with intestinal differentiation of gastric cancer. Cancer Sci. 2012; 103(9):1744-50. PMC: 7659384. DOI: 10.1111/j.1349-7006.2012.02353.x. View

18.

Oue N, Hamai Y, Mitani Y, Matsumura S, Oshimo Y, Aung P . Gene expression profile of gastric carcinoma: identification of genes and tags potentially involved in invasion, metastasis, and carcinogenesis by serial analysis of gene expression. Cancer Res. 2004; 64(7):2397-405. DOI: 10.1158/0008-5472.can-03-3514. View

19.

Lai Y, Wu L, Li P, Wu W, Yang S, Xia P . Tumour budding is a reproducible index for risk stratification of patients with stage II colon cancer. Colorectal Dis. 2013; 16(4):259-64. DOI: 10.1111/codi.12454. View

20.

Wu B, Crampton S, Hughes C . Wnt signaling induces matrix metalloproteinase expression and regulates T cell transmigration. Immunity. 2007; 26(2):227-39. PMC: 1855210. DOI: 10.1016/j.immuni.2006.12.007. View